Payment overview · 2025
General Payments
$72.30
4 reported records · 4 companies
Healthcare provider profile · identity verified
Calixto Cazano, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARAGOULD, AR · NPI 1114289899
Verified facts
What the public records show
CMS Open Payments records show Calixto Cazano, M.D. received $72.30 in general payments during 2025 across 4 reported records.
Verona Pharma, Inc. accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.03 | 33.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.48 | 26.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.58 | 20.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.21 | 19.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $72.30 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 458 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 363 | 63 |
| Gabapentin | Gabapentin | 277 | 55 |
| Metformin Hcl | Metformin Hcl | 260 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 35 |
| Furosemide | Furosemide | 197 | 42 |
| Omeprazole | Omeprazole | 187 | 37 |
| Tramadol Hcl | Tramadol Hcl | 187 | 30 |
| Lisinopril | Lisinopril | 179 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 28 |
| Trazodone Hcl | Trazodone Hcl | 155 | 27 |
| Losartan Potassium | Losartan Potassium | 140 | 28 |
| Potassium Chloride | Potassium Chloride | 133 | 39 |
| Carvedilol | Carvedilol | 129 | 22 |
| Montelukast Sodium | Montelukast Sodium | 129 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 18 |
| Ozempic | Semaglutide | 117 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 20 |
| Sertraline Hcl | Sertraline Hcl | 113 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 39 |
| Simvastatin | Simvastatin | 107 | 17 |
| Meloxicam | Meloxicam | 103 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 20 |
| Famotidine | Famotidine | 101 | 25 |
| Clonazepam | Clonazepam | 90 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 23 |
| Farxiga | Dapagliflozin Propanediol | 74 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 16 |
| Diazepam | Diazepam | 71 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 17 |
| Allopurinol | Allopurinol | 69 | 13 |
| Buspirone Hcl | Buspirone Hcl | 67 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 12 |
| Topiramate | Topiramate | 64 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 12 |
| Jardiance | Empagliflozin | 56 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | suppressed |
| Celecoxib | Celecoxib | 55 | 16 |
| Eliquis | Apixaban | 55 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Spironolactone | Spironolactone | 43 | 11 |
| Glipizide | Glipizide | 42 | 12 |
| Mirtazapine | Mirtazapine | 42 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 40 | 14 |
| Brilinta | Ticagrelor | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | suppressed |
| Prednisone | Prednisone | 38 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 18 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 24 |
| Estradiol | Estradiol | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 24 | 19 |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Primidone | Primidone | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72.30 · 4 records | Verona Pharma, Inc. | FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, Ohtuvayre, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error